At the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases, Roche outlined the effectiveness of digital health technologies (DHTs) in providing more sensitive measures of ...

The ASCEND trial evaluated the safety, tolerability, and efficacy of solengepras and aimed to establish its potential to ...

Boujis 3.0 aka Gallery has opened its doors in Kensington, with the same quartet of entrepreneurs behind it. But there's one ...

The pivotal, Phase III study will evaluate the change in average daily “OFF” time in solengepras patients compared to placebo ...

This investigational treatment was generally well tolerated with no serious adverse events; fewer adverse events related to non-motor symptoms were reported in the solengepras arm Pivotal Phase 3 ...

Sleep deficiency was associated with atrophy of the inferior parietal region, which is observed in early Alzheimer's disease.

At ACS spring meeting, researchers say nitrate metabolizers in the gut may promote α-synuclein aggregation through multistep redox mechanism ...

It's an honor to be a part of this process to, as a basic scientist, be able to play a small role in improving the lives of ...

Professor Karlo Malaga leads research focusing on pinpointing specific areas in the subthalamic region where deep brain ...

From family members, to friends, to beloved members of society, Parkinson’s disease impacts more than 10 million people ...

Existing research indicates that the accuracy of a Parkinson's disease diagnosis hovers between 55% and 78% in the first five years of assessment. That's partly because Parkinson's sibling movement ...

With over 10 million people affected worldwide, Parkinson's disease is the fastest-growing neurological disorder. More than ...